Changes in Patient Functioning and Disability: Results from Two Phase 3 Double-Blind Placebo-Controlled Clinical Trials Evaluating Galcanezumab for Episodic Migraine Prevention (EVOLVE-1 and EVOLVE-2)

被引：0
|
作者：
Ford, J. [1 ]
Ayer, D. [1 ]
Zhang, Q. [2 ]
Carter, J. [2 ]
Skljarevski, V [2 ]
Aurora, S. [2 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
HEADACHE | 2018年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PS37
引用
收藏
页码：171 / 172
页数：2
相关论文
共 50 条
  • [1] Changes in patient functioning and disability: results from two phase 3 double-blind placebo-controlled clinical trials evaluating galcanezumab for episodic migraine prevention (EVOLVE-1 and EVOLVE-2)
    Ford, Janet H.
    Ayer, David W.
    Zhang, Qi
    Carter, Jeffrey N.
    Skljarevski, Vladimir
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [2] Analysis of Initial Non Responders to Galcanezumab in Patients with Episodic or Chronic Migraine: Results from the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Trials
    Nichols, Russell M.
    Ruff, Dustin
    Pearlman, Eric
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [3] Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies
    Nichols, Russell
    Doty, Erin
    Sacco, Sara
    Ruff, Dustin
    Pearlman, Eric
    Aurora, Sheena K.
    HEADACHE, 2019, 59 (02): : 192 - 204
  • [4] 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies
    Rosen, Noah
    Pearlman, Eric
    Ruff, Dustin
    Day, Kathleen
    Nagy, Abraham Jim
    HEADACHE, 2018, 58 (09): : 1347 - 1357
  • [5] Analysis of Initial Non-Responders to Galcanezumab in Patients with Episodic or Chronic Migraine: Results from the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Trials
    Nichols, R.
    Ruff, D.
    Pearlman, E.
    Aurora, S.
    HEADACHE, 2018, 58 : 173 - 174
  • [6] Persistence of effect of galcanezumab in patients with episodic or chronic migraine: phase 3, randomized, double-blind, placebo controlled EVOLVE-1, EVOLVE-2 and REGAIN studies
    Aurora, Sheena K.
    Zhang, Qi
    Stauffer, Virginia L.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [7] Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
    Jessica Ailani
    J. Scott Andrews
    Mallikarjuna Rettiganti
    Robert A. Nicholson
    The Journal of Headache and Pain, 2020, 21
  • [8] Effect of galcanezumab following double-blind treatment in patients with migraine: results from EVOLVE-1 and EVOLVE-2
    Zhang, Qi
    Morrow, Paula A.
    Stauffer, Virginia L.
    Skljarevski, Vladimir
    Pearlman, Eric M.
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [9] Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
    Ailani, Jessica
    Andrews, J. Scott
    Rettiganti, Mallikarjuna
    Nicholson, Robert A.
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [10] GALCANEZUMAB EFFECTS IN ADULT PATIENTS WITH EPISODIC OR CHRONIC MIGRAINE ARE PERSISTENT: DATA FROM THREE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EVOLVE-1, EVOLVE-2, AND REGAIN STUDIES
    Aurora, S.
    Zhang, Q.
    Stauffer, V.
    CEPHALALGIA, 2018, 38 : 50 - 51
12345